Rising Tide Of Cancer Is Anticipated To Fuels The Liquid Biopsy For Cancer Diagnostics Market Growth: Strategic Insights Driving Liquid Biopsy For Cancer Diagnostics Market Momentum in 2025

Use code ONLINE30 to get 30% off on global market reports and stay ahead of tariff changes, macro trends, and global economic shifts.

How Large Will the Liquid Biopsy For Cancer Diagnostics Market Size By 2025?
In recent times, the market size for liquid biopsy for cancer diagnostics has been on a dramatic increase. Projected to expand from $9.23 billion in 2024 to $10.78 billion in 2025, it exhibits a compound annual growth rate (CAGR) of 16.8%. Factors contributing to the growth during the historic period include advancements in the field of genomic research, a heightened understanding of the advantages of liquid biopsy, a surge in cancer prevalence, heightened need for non-invasive methods of cancer testing, and the enlargement of precision medicine initiatives.

How Big Is the Liquid Biopsy For Cancer Diagnostics Market Size Expected to Grow by 2029?
The market size for liquid biopsy in cancer diagnostics is anticipated to witness a swift expansion in the coming years, reaching $19.32 billion by 2029 with a compound annual growth rate (CAGR) of 15.7%. The anticipated growth in this forecast period can be attributed to factors such as the incorporation of liquid biopsy into regular cancer diagnostic procedures, the use of liquid biopsy for early detection of cancer, the proliferation of cancer screening initiatives, an increasing emphasis on individualized medicine in oncology, and heightened funding for research into liquid biopsy. Prominent trends predicted for the forecast period encompass the emergence of multi-omics liquid biopsy methods, the incorporation of artificial intelligence into liquid biopsy analysis, the broadening of liquid biopsy applications beyond the sphere of oncology, the creation of blood-based biomarkers for cancer, and the tailoring of liquid biopsy tests for specific types of cancer.

View the full report here:
https://www.thebusinessresearchcompany.com/report/liquid-biopsy-for-cancer-diagnostics-global-market-report

Which Key Market Drivers Powering Liquid Biopsy For Cancer Diagnostics Market Expansion and Growth?
The increasing prevalence of cancer is anticipated to stimulate the expansion of the liquid biopsy for cancer diagnostics industry. Cancer, a broad classification of diseases that can materialize in almost any organ or tissue when rogue cells multiply beyond control, cross their usual borders, and either metastasize to other organs or infiltrate adjacent body parts, boosts the demand for diagnostic procedures. These procedures include early detection of cancer or tumor relapse, patient-specific risk evaluation, and therapy monitoring. These assessments allow liquid biopsy to fully capture the disease's nature as tumor cells or their products are dispersed from all primary or metastatic tumor locations, providing comprehensive, real-time data on tumor cell adaptation, therapeutic objectives, and therapy resistance mechanisms. For example, the National Cancer Institute, a US government agency, reported around 18.1 million cancer survivors in the US in May 2024. This number is predicted to escalate to 22.5 million by 2032. The annual new cancer cases are forecasted to reach 29.9 million by 2040, with cancer-related fatalities expected to rise to 15.3 million. Consequently, the escalating prevalence of cancer is steering the growth of the liquid biopsy for cancer diagnostics industry.

Get your free sample here:
https://www.thebusinessresearchcompany.com/sample.aspx?id=12205&type=smp

Which Fast-Growing Trends Are Poised to Disrupt the Liquid Biopsy For Cancer Diagnostics Market?
The rising trend of product innovations is making considerable headway in the liquid biopsy for cancer diagnostics market. Major firms in this market are focusing on generating innovative products to solidify their market presence. For example, BostonGene, a biomedical software company in the US, introduced new liquid biopsy solutions in June 2023 to assist in identifying critical gene alterations. The expansion of the test portfolio will accelerate the development of new assays, analytical instruments, and workflows, thereby providing precision medicine to patients. It will encompass multiple AI-driven molecular and immunological profiling techniques to evaluate tumors, microenvironments, and host immunity. Furthermore, it aids immunotherapy treatment, delivers information on a patient's immune-related issues, and tracks disease progression and treatment response.

What Are the Emerging Segments in the Liquid Biopsy For Cancer Diagnostics Market?
The liquid biopsy for cancer diagnostics market covered in this report is segmented -

1) By Type: Product, Services
2) By Sample: Blood, Urine, Saliva
3) By Cancer: Lung Cancer, Breast Cancer, Colon Cancer, Other Cancers
4) By End-User: Hospitals, Diagnostic Centers, Other End-Users

Subsegments:
1) By Product: Circulating Tumor Cells (CTCs) Detection Kits, Circulating Tumor DNA (ctDNA) Detection Kits, Exosome Isolation Kits, Sample Collection Devices
2) By Services: Testing Services, Analytical Services, Bioinformatics Services

Tailor your insights and customize the full report here:
https://www.thebusinessresearchcompany.com/customise?id=12205&type=smp

Who Are the Global Leaders in the Liquid Biopsy For Cancer Diagnostics Market?
Major companies operating in the liquid biopsy for cancer diagnostics market include F. Hoffman La Roche Ltd., Thermo Fisher Scientific Inc., Agilent Technologies Inc., Illumina Inc., The Menarini Group, Bio-Rad Laboratories Inc., QIAGEN Inc., Exact Sciences Corporation, Bio-Techne Corporation, ArcherDX Inc., Neogenomics Laboratories Inc., Guardant Health Inc., Myriad Genetics Inc., Foundation Medicine Inc., Amoy Diagnostics Co. Ltd., Biocartis Group NV, Biodesix Inc., MDx Health Inc., Sysmex Inostics Inc., Biocept Inc., Agena Bioscience Inc., Laboratory for Advanced Medicine (LAM) Inc., MiRXES Pte Ltd., Inivata Limited, Resolution Bioscience Inc., SAGA Diagnostics AB, NuProbe Inc., Personal Gemone Diagnostics Inc., Pathway Genomics Corporation, Angle PLC

Which are the Top Profitable Regional Markets for the Liquid Biopsy For Cancer Diagnostics Industry?
North America was the largest region in the liquid biopsy for cancer diagnostics market in 2024. Asia-Pacific is expected to be the fastest-growing region in the liquid biopsy for cancer diagnostics market report during the forecast period. The regions covered in the liquid biopsy for cancer diagnostics market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Purchase the full report today:
https://www.thebusinessresearchcompany.com/purchaseoptions.aspx?id=12205

This Report Supports:
1. Business Leaders & Investors - To identify growth opportunities, assess risks, and guide strategic decisions.
2. Manufacturers & Suppliers - To understand market trends, customer demand, and competitive positioning.
3. Policy Makers & Regulators - To track industry developments and align regulatory frameworks.
4. Consultants & Analysts - To support market entry, expansion strategies, and client advisory work.

Connect with us on:
LinkedIn: https://in.linkedin.com/company/the-business-research-company,
Twitter: https://twitter.com/tbrc_info,
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ.

Contact Us
Europe: +44 7882 955267,
Asia: +91 88972 63534,
Americas: +1 310-496-7795 or
Email: mailto:info@tbrc.info

Learn More About The Business Research Company
With over 15,000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Our flagship product, the Global Market Model delivers comprehensive and updated forecasts to support informed decision-making.

This release was published on openPR.